Trial Profile
Multicenter Open Label Expanded Access-Program of Pegylated Interferon Alfa-2a (Pegasys) in Patients With Chronic Myelogenous Leukemia (CML)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Roche
- 08 Apr 2016 Status changed from active, no longer recruiting to completed.
- 20 Jun 2006 New trial record.